Rohan PalekarCEO at 89Bio
Rohan Palekar is a seasoned C-suite executive with over 25 years of experience in the biopharmaceutical industry. Rohan is the CEO of 89Bio, a clinical-stage company focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Previously, Rohan was the president and CEO of Avanir Pharmaceuticals (2015-2017) after serving as its EVP-Chief Operating Officer (2015). Rohan joined Avanir in 2012 as Chief Commercial Officer (CCO) and as part of the senior leadership team led the organization through a dynamic growth phase. Avanir was acquired by Otsuka Pharmaceuticals in 2015. Prior to Avanir, Rohan served as the CCO of Medivation where he oversaw commercial, medical affairs, CMC & manufacturing. Earlier in his career, Rohan spent 16 years at Johnson & Johnson in various senior commercial and strategic management roles including worldwide VP of immunology. Rohan holds an MBA from the Amos Tuck School at Dartmouth College and a BA/BS in law and accounting from the University of Bombay.